Jun 26 |
Jaguar Health regains compliance with Nasdaq's listing rule
|
Jun 26 |
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
|
Jun 21 |
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
|
Jun 12 |
Jaguar Health slips after update on anti-diarrheal therapy
|
Jun 12 |
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
|
Jun 7 |
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
May 29 |
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
|
May 28 |
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
|
May 23 |
Jaguar Health extends losses as reverse stock split takes effect
|
May 23 |
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
|